Antibodies that activate beta 2 integrins can generate different ligand binding states

Area of Science:

• Cell Biology
• Immunology
• Molecular Biology

Background:

• Beta 2 integrins are crucial for immune cell adhesion and function.
• K562 cells, a human erythroleukemic line, lack endogenous beta 2 integrin expression.
• Understanding integrin activation and ligand binding is key to immune response modulation.

Purpose of the Study:

• To investigate the functional expression of beta 2 integrins in a non-hematopoietic cell line.
• To determine how different antibodies targeting CD18 affect ligand binding specificity.
• To explore the activation requirements for transfected complement receptor type 3 and p150,95.

Main Methods:

• Gene transfection of K562 cells with beta 2 integrin subunits.
• Stimulation of transfected cells using antibodies against CD18.
• Assessment of cell adhesion to protein-coated substrates.
• Analysis of differential ligand binding states induced by antibodies.

Main Results:

• Transfected K562 cells exhibited minimal baseline adhesion but could be activated to bind substrates.
• Two distinct CD18 antibodies induced different ligand binding states in LFA-1.
• Antibody-activated complement receptor type 3 and p150,95 showed binding to protein surfaces under specific conditions.
• Differential activation requirements were observed for complement receptor type 3 and p150,95.

Conclusions:

• Beta 2 integrin expression can be functionally reconstituted in K562 cells.
• CD18 antibody-mediated activation provides a tool to study integrin-ligand interactions.
• This system allows for the investigation of specific integrin subtypes and their activation mechanisms.